Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) CTO Sells $26,953.50 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 5,285 shares of the firm’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.10, for a total value of $26,953.50. Following the completion of the transaction, the chief technology officer directly owned 192,171 shares of the company’s stock, valued at $980,072.10. The trade was a 2.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Thursday, June 25th, Abhimanyu Verma sold 6,944 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $5.51, for a total value of $38,261.44.

SOPHiA GENETICS Stock Performance

NASDAQ:SOPH opened at $5.82 on Friday. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06. SOPHiA GENETICS SA has a 52-week low of $2.92 and a 52-week high of $6.30. The firm has a market cap of $488.24 million, a price-to-earnings ratio of -11.19 and a beta of 0.96. The business’s fifty day moving average is $5.16 and its 200 day moving average is $4.98.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The company had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on SOPH shares. BTIG Research reissued a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a report on Monday, June 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $7.50.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS in the fourth quarter valued at approximately $49,000. Squarepoint Ops LLC bought a new stake in SOPHiA GENETICS during the third quarter valued at approximately $49,000. First Dallas Securities Inc. purchased a new position in SOPHiA GENETICS in the 1st quarter worth approximately $50,000. Quadrature Capital Ltd purchased a new position in SOPHiA GENETICS in the 4th quarter worth approximately $54,000. Finally, XTX Topco Ltd bought a new position in shares of SOPHiA GENETICS in the 4th quarter worth $55,000. 31.59% of the stock is currently owned by institutional investors.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.